18+ · Research use only
Cagrilintide Philippines
Cagrilintide is a peptide sold by Primara Labs for research use only. It sells as a 10 pack at ₱1,216 a vial; a single vial is ₱1,990 on request. Metro Manila orders before 12 noon arrive the same day; provinces take 1 to 2 days Luzon, 2 to 3 Visayas, 3 to 5 Mindanao. Lab testing: no report published yet, scheduled, see primaralabs.com/coa.
Peptide studied in Phase 3 human trials. Lyophilized powder, stocked in Metro Manila and sold in 10 packs. For laboratory research use only.
Sold as a 10 pack
Pack price replaces the 10% off. One compound per pack.
Pack price replaces the standing 10% off; they don't stack. One compound per pack.
Single vial ₱1,990, on request
Request a single vialCheck out once for the whole cart. Pay by QR, confirm on WhatsApp.
Add more compounds if you like, then check out once. You pay by QR on your order page and send the screenshot on WhatsApp.
In the Philippines
GCash · Maya · QR Ph bank transfer · InstaPay
From abroad
- International transfer
Wise · International bank transfer · Zelle · Crypto
Payment details are sent in the WhatsApp chat once your order is confirmed.
Order by 12 noon on a weekday for same-day Metro Manila
Includes water, syringes, pads · plain box
60-day money-back guaranteeTerms
Order by 12 noon on a weekday for same-day delivery in Metro Manila
Free courier nationwide · Luzon 1-2 days · Visayas 2-3 days · Mindanao 3-5 days
Everything to reconstitute is included
10 x 3ml water · 100 syringes · 100 pads · plain outer packaging
60-day money-back guarantee
If an accredited independent laboratory reports that this vial is not the compound on the label, we refund what you paid for it. Evidence within 60 calendar days of delivery; you do not send anything back. Terms
Delivery proof
Real orders, really delivered

Metro Manila · Same-day
Shipped 1:57 PM, received 2:33 PM. Same day, 36 minutes.

Metro Manila · Customer reply
"Surprised din po ako. Magoorder ako ulit kapag naubos na." They came back and reordered.

Quezon City · Repeat customer
Delivered 11:34 PM. Three weeks later: "Can I order again." "Primara I can say was the best choice."
Real WhatsApp and courier screenshots. Names, numbers and addresses are blacked out.
Updated 16 November 2026
- Human evidence
- Phase 3
- Manufacturing
- cGMP · ISO 9001 · ISO 13485
- Latest batch report
- Scheduled, see /coa
- Storage
- 2 to 8 °C sealed
Cagrilintide in the Philippines
Cagrilintide is a long-acting analogue of amylin, the hormone released alongside insulin that signals fullness. It acts at the amylin receptors and at the calcitonin receptor, and Novo Nordisk has studied it on its own and combined with semaglutide in obesity trials.
Its largest trial, REDEFINE 1, a phase 3 trial in adults with obesity or overweight, included a cagrilintide-alone arm as well as the combination. The larger weight figures quoted for cagrilintide usually come from the combination with semaglutide, which is a different result. Each figure, its side effects and its source are set out in the research section below.
Cagrilintide is sold here as a 10 pack of 5mg vials, with a single vial available on request in the chat. Keep every vial sealed in the fridge at 2 to 8°C until it is used. Add the pack to the cart or start a WhatsApp chat from this page; we confirm the peso total before anything is paid. Ordered before 12 noon on a weekday, Metro Manila addresses receive the same day. For context on the amylin and incretin compounds in this catalogue, see the philippinespeptides.com peptide guides.
Regulatory status
Cagrilintide. FDA Philippines: not established. US FDA: Investigational, approved for no use. A US FDA decision on the cagrilintide and semaglutide combination, and the phase 3 programme for cagrilintide alone. Checked 16 November 2026.
Sold for laboratory research only, not for human consumption. Primara Labs does not give medical advice or dosing guidance. Regulatory Status Tracker
Laboratory handling
Reconstitution reference
| BAC water added | Resulting concentration | Note |
|---|---|---|
| 1.0 ml | 5 mg/ml | Highest concentration, smallest volumes |
| 2.0 ml | 2.5 mg/ml | Common reference dilution |
Reconstitute with bacteriostatic water. Reference values are for laboratory preparation only. Other volumes: reconstitution calculator, prefilled for Cagrilintide 5mg.
Handling and storage
Sealed vials
Store sealed lyophilised vials refrigerated at 2 to 8 °C, away from light.
Primara Labs storage instructionAdding diluent
Add the diluent slowly down the inside wall of the vial rather than straight onto the powder.
Mixing
The US prescribing instructions for tesamorelin, a lyophilised peptide medicine, tell users to swirl the vial to mix the powder and liquid, and not to shake it.
Tesamorelin US instructions for use, DailyMed · checked 23 September 2026Appearance
The same instructions say not to use the solution if it is cloudy, discoloured or has particles in it.
Tesamorelin US instructions for use, DailyMed · checked 23 September 2026After the stopper is punctured
CDC guidance, citing USP chapter 797, is that a multi-dose vial once opened is dated and discarded within 28 days unless the manufacturer states another date, and never used past its original expiry.
CDC, Preventing Unsafe Injection Practices · checked 23 September 2026Benefits studied
Body-weight reduction
Phase 3 humanIn REDEFINE 1, a 68-week phase 3 trial of 3,417 adults with obesity, or overweight with a weight-related condition, and without diabetes, the cagrilintide-alone arm lost a mean 11.5% of body weight against 3.0% on placebo (treatment-policy estimand).
Garvey WT et al. N Engl J Med 2025 (REDEFINE 1) · checked 16 November 2026Body-weight reduction combined with semaglutide
Phase 3 humanIn the same REDEFINE 1 trial, adults given cagrilintide in combination with semaglutide lost a mean 20.4% of body weight at 68 weeks against 3.0% on placebo; this is a combination result, not a result for cagrilintide alone.
Garvey WT et al. N Engl J Med 2025 (REDEFINE 1) · checked 16 November 2026Body-weight reduction in a dose-finding trial
Phase 2 humanIn a 26-week phase 2 dose-finding trial in adults with overweight or obesity, mean body weight fell between 6.0% and 10.8% across the cagrilintide arms against 3.0% on placebo.
Lau DCW et al. Lancet 2021, PubMed 34798060 · checked 16 November 2026
Side effects reported
In the 26-week phase 2 trial, gastrointestinal adverse events, mainly nausea, occurred in 41% to 63% of participants across the cagrilintide arms against 32% on placebo.
Lau DCW et al. Lancet 2021, PubMed 34798060 · checked 16 November 2026In REDEFINE 1, gastrointestinal adverse events affected 79.6% of the group given cagrilintide combined with semaglutide against 39.9% on placebo, mostly transient and mild to moderate; this figure is for the combination.
Garvey WT et al. N Engl J Med 2025 (REDEFINE 1) · checked 16 November 2026Findings are described as the research reported them, with the level of evidence for each. They are not a claim about any vial sold here, which is supplied for laboratory research use only.
How it works
Cagrilintide is a long-acting analogue of amylin, a hormone released with insulin that signals fullness. It activates both the amylin receptors and the calcitonin receptor; a 2025 structural study described how it binds them.
Targets: Amylin receptors and the calcitonin receptor
What the research shows
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk and approved nowhere. In the phase 3 REDEFINE 1 trial, adults on cagrilintide alone lost a mean 11.5% of body weight over 68 weeks against 3.0% on placebo; most of its human data come from combinations with semaglutide. Gastrointestinal effects, mainly nausea, were the most common adverse events.
Lab report: scheduled, see primaralabs.com/coa. No batch report for Cagrilintide is published yet.
- Type
- Long-acting amylin analogue
- Presentation
- Lyophilized powder, 5 mg / vial
- Vial size
- 5mg
- Catalogue code
- PRM-022
PubChem could not be reached when this SKU was added on 16 November 2026, so no formula, weight or CAS is published from it yet.
Frequently asked
Cagrilintide questions, answered
How much is Cagrilintide in the Philippines?
At Primara Labs, Cagrilintide 5mg sells as a 10 pack at ₱1,216 per vial (₱12,160 total). A single vial is ₱1,990, available on request on WhatsApp. Prices are in pesos and the pack price is shown on the product page before you order.
Where can I buy Cagrilintide in the Philippines?
Primara Labs sells Cagrilintide 5mg as a 10 pack, with single vials on request on WhatsApp. Two ways to order: add to cart and pay by QR (GCash, Maya, QR Ph, InstaPay), or message us on WhatsApp to pay by Wise, international bank transfer, Zelle or crypto.
Do you deliver Cagrilintide to Cebu, Davao and the provinces?
Yes. Metro Manila: same day before 12 noon, Grab Express / Lalamove, ₱150; Luzon: 1 to 2 business days, J&T Express, ₱250; Visayas: 2 to 3 business days, J&T Express, ₱250; Mindanao: 3 to 5 business days, J&T Express, ₱300. Cebu is in the Visayas and Davao in Mindanao. Courier is free on orders over ₱10,000 anywhere in the Philippines. Below that, a Metro Manila rider is ₱150, J&T Express is ₱250 to Luzon and the Visayas and ₱300 to Mindanao.
Is Cagrilintide FDA approved in the Philippines?
Cagrilintide. FDA Philippines: not established. US FDA: Investigational, approved for no use. A US FDA decision on the cagrilintide and semaglutide combination, and the phase 3 programme for cagrilintide alone. Checked 16 November 2026. Primara Labs supplies it for research use only; it is not for human consumption.
Why is this sold as a 10-pack?
Cagrilintide is sold in 10-packs, at ₱1,216 per vial. Single vials are available on request via WhatsApp at ₱1,990. Delivery times are the same as for the rest of the catalogue.
Is cagrilintide the same as the cagrilintide and semaglutide combination?
No. Cagrilintide is the amylin analogue on its own. The combination studied by Novo Nordisk pairs it with semaglutide, and its trial results belong to the combination, not to cagrilintide alone. This vial contains cagrilintide only.
What is Cagrilintide studied for?
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk and approved nowhere. In the phase 3 REDEFINE 1 trial, adults on cagrilintide alone lost a mean 11.5% of body weight over 68 weeks against 3.0% on placebo; most of its human data come from combinations with semaglutide. Gastrointestinal effects, mainly nausea, were the most common adverse events.
What side effects were reported for Cagrilintide?
In the 26-week phase 2 trial, gastrointestinal adverse events, mainly nausea, occurred in 41% to 63% of participants across the cagrilintide arms against 32% on placebo. In REDEFINE 1, gastrointestinal adverse events affected 79.6% of the group given cagrilintide combined with semaglutide against 39.9% on placebo, mostly transient and mild to moderate; this figure is for the combination.
How should Cagrilintide be stored?
Store sealed lyophilised vials refrigerated at 2 to 8 °C, away from light. CDC guidance, citing USP chapter 797, is that a multi-dose vial once opened is dated and discarded within 28 days unless the manufacturer states another date, and never used past its original expiry.
Does Primara Labs publish lab reports for Cagrilintide?
Lab report: scheduled, see primaralabs.com/coa. No batch report for Cagrilintide is published yet.
All compounds supplied by Primara Labs are for laboratory research use only and are not for human consumption, diagnostic or therapeutic use. Statements on this page describe published research and have not been evaluated by the Philippine FDA. See Research Use Only terms.
